<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823082</url>
  </required_header>
  <id_info>
    <org_study_id>IG0801</org_study_id>
    <nct_id>NCT00823082</nct_id>
  </id_info>
  <brief_title>Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass</brief_title>
  <official_title>A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effects of preoperative antithrombin
      supplementation in patients undergoing cardiac surgery with cardiopulmonary bypass in order
      to maintain antithrombin levels in a range greater than 58% of functional activity and,
      eventually, to decrease negative clinical outcomes during the ICU stay.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative ATIII Levels at the ICU Admission</measure>
    <time_frame>ICU admission</time_frame>
    <description>Measurement of postoperative ATIII functional activity at ICU admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission</measure>
    <time_frame>ICU admission</time_frame>
    <description>Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Postoperative Myocardial Infarction</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects with postoperative myocardial infarction defined through enzymatic criteria plus new Q-waves at the electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Adverse Neurologic Outcome</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects with adverse neurologic outcome defined as: coma, stroke or psychotic behaviors lasting &gt;12 hours after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Thromboembolic Events</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects with thromboembolic events defined as perioperative myocardial infarction, stroke, mesenteric infarction, peripheral thromboembolism and pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Stay Duration</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Postoperative Mortality</measure>
    <time_frame>70 days after ICU admission (maximum)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heparin Resistance</measure>
    <time_frame>Immediately after anesthesia induction</time_frame>
    <description>Percentage of subjects with heparin resistance defined as failure to reach an activated clotting time &gt;450 seconds after a dose of up to 400 IU/kg of heparin, or failure to maintain this activated clotting time value despite heparin supplementations of 100 IU/kg per each dose with an interval of at least 30 minutes between doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Blood Loss in First 12 Hours</measure>
    <time_frame>ICU admission through 12 hours post-operative</time_frame>
    <description>Blood loss defined as the amount of blood collected in the cardiotomy reservoir from ICU admission through the following 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Blood Products</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Number of units of packed red blood cells, fresh frozen plasma, and/or platelets needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Needing Surgical Re-exploration</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects needing surgical re-exploration resulting from bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Low Cardiac Syndrome</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects with low cardiac syndrome defined as the need for major inotropic support or intra-aortic balloon pump</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Renal Dysfunction</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Percentage of subjects with renal dysfunction defined as an increase of serum creatinine levels to &gt;2.0 and twice the baseline level or need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Duration</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>During ICU stay (maximum 70 days)</time_frame>
    <description>Length of hospital stay (days) in both groups was defined as the discharge date minus the surgery date plus 1 day, during a maximum of 70 days after ICU admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Acquired Antithrombin III Deficiency</condition>
  <condition>Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>Antithrombin III treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative ATIII supplementation administered immediately after anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No preoperative ATIII supplementation administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III</intervention_name>
    <description>Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
    <arm_group_label>Antithrombin III treatment group</arm_group_label>
    <other_name>Anbinex</other_name>
    <other_name>ATIII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  At least 18 years of age

          -  Subject needed elective cardiac surgery with cardiopulmonary bypass except for heart
             transplantation

          -  Subject had a baseline ATIII level of less than 100% and equal to or above 60%

          -  Subject signed the informed consent form

          -  Subject was willing to comply with all aspects of the protocol, including blood
             sampling, for the total duration of the study

        Exclusion Criteria:

          -  Documented congenital ATIII deficiency or ATIII levels below 60%

          -  Subject had a baseline ATIII level of 100% or higher

          -  Subject needed emergency (non-elective) surgery

          -  Subject needed heart transplantation

          -  History of anaphylactic reaction(s) to blood or blood components

          -  Allergies to excipients

          -  Subject was pregnant

          -  Subject had any medical condition that according to the investigators judgment worsens
             the surgical outcome above the expected

          -  Subject had any medical condition which is likely to interfere with the evaluation of
             the study treatment and/or the satisfactory conduct of the trial according to the
             investigators judgment

          -  Subject had participated in any another investigational study within the last 30 days
             previous to the inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Ranucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <state>Lombardy</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <results_first_submitted>April 5, 2016</results_first_submitted>
  <results_first_submitted_qc>June 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2016</results_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antithrombin</keyword>
  <keyword>ATIII</keyword>
  <keyword>acquired deficiency</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>surgery</keyword>
  <keyword>complications</keyword>
  <keyword>postoperative outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antithrombin III Treatment Group</title>
          <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>No preoperative ATIII supplementation administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat/Per Protocol Populations</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>206 subjects were randomized; six were screen failures. 100 subjects in the Anbinex treatment group and 94 subjects in the control group were included in the Intent-to-treat and Per-protocol populations (6 subjects in the control group were excluded). 199 subject were included in the Safety population (100 Anbinex and 99 control).</population>
      <group_list>
        <group group_id="B1">
          <title>Antithrombin III Treatment Group</title>
          <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>No preoperative ATIII supplementation administered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.51" spread="10.48"/>
                    <measurement group_id="B2" value="67.63" spread="11.18"/>
                    <measurement group_id="B3" value="67.05" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative ATIII Levels at the ICU Admission</title>
        <description>Measurement of postoperative ATIII functional activity at ICU admission</description>
        <time_frame>ICU admission</time_frame>
        <population>Intent-to-treat set and Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative ATIII Levels at the ICU Admission</title>
          <description>Measurement of postoperative ATIII functional activity at ICU admission</description>
          <population>Intent-to-treat set and Per-protocol set</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.06" spread="13.74"/>
                    <measurement group_id="O2" value="64.70" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission</title>
        <description>Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission</description>
        <time_frame>ICU admission</time_frame>
        <population>Intent-to treat set and Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission</title>
          <description>Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission</description>
          <population>Intent-to treat set and Per-protocol set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Postoperative Myocardial Infarction</title>
        <description>Percentage of subjects with postoperative myocardial infarction defined through enzymatic criteria plus new Q-waves at the electrocardiogram</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Postoperative Myocardial Infarction</title>
          <description>Percentage of subjects with postoperative myocardial infarction defined through enzymatic criteria plus new Q-waves at the electrocardiogram</description>
          <population>Intent-to-treat set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up visit (Anbinex n=76, Control n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU discharge visit (Anbinex n=99, Control n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At ICU discharge visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6115</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Adverse Neurologic Outcome</title>
        <description>Percentage of subjects with adverse neurologic outcome defined as: coma, stroke or psychotic behaviors lasting &gt;12 hours after extubation</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Adverse Neurologic Outcome</title>
          <description>Percentage of subjects with adverse neurologic outcome defined as: coma, stroke or psychotic behaviors lasting &gt;12 hours after extubation</description>
          <population>Intent-to-treat set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up visit (Anbinex n=75, Control n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU discharge visit (Anbinex n=99, Control n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1211</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ICU discharge visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Thromboembolic Events</title>
        <description>Percentage of subjects with thromboembolic events defined as perioperative myocardial infarction, stroke, mesenteric infarction, peripheral thromboembolism and pulmonary embolism</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Thromboembolic Events</title>
          <description>Percentage of subjects with thromboembolic events defined as perioperative myocardial infarction, stroke, mesenteric infarction, peripheral thromboembolism and pulmonary embolism</description>
          <population>Intent-to-treat set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up visit (Anbinex n=76, Control n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU discharge visit (Anbinex n=99, Control n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ICU discharge visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4870</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Stay Duration</title>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set. One subject in the control group was missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Stay Duration</title>
          <population>Intent-to-treat set. One subject in the control group was missing this data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3897</p_value>
            <method>Hodges-Lehmann test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Postoperative Mortality</title>
        <time_frame>70 days after ICU admission (maximum)</time_frame>
        <population>Intent-to-treat set. One subject in the control group was missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Postoperative Mortality</title>
          <population>Intent-to-treat set. One subject in the control group was missing this data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heparin Resistance</title>
        <description>Percentage of subjects with heparin resistance defined as failure to reach an activated clotting time &gt;450 seconds after a dose of up to 400 IU/kg of heparin, or failure to maintain this activated clotting time value despite heparin supplementations of 100 IU/kg per each dose with an interval of at least 30 minutes between doses</description>
        <time_frame>Immediately after anesthesia induction</time_frame>
        <population>Intent-to-treat set. One subject in the Antithrombin III treatment group was missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Heparin Resistance</title>
          <description>Percentage of subjects with heparin resistance defined as failure to reach an activated clotting time &gt;450 seconds after a dose of up to 400 IU/kg of heparin, or failure to maintain this activated clotting time value despite heparin supplementations of 100 IU/kg per each dose with an interval of at least 30 minutes between doses</description>
          <population>Intent-to-treat set. One subject in the Antithrombin III treatment group was missing this data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Blood Loss in First 12 Hours</title>
        <description>Blood loss defined as the amount of blood collected in the cardiotomy reservoir from ICU admission through the following 12 hours</description>
        <time_frame>ICU admission through 12 hours post-operative</time_frame>
        <population>Intent-to-treat set. One subject in the Antithrombin III treatment group was missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Blood Loss in First 12 Hours</title>
          <description>Blood loss defined as the amount of blood collected in the cardiotomy reservoir from ICU admission through the following 12 hours</description>
          <population>Intent-to-treat set. One subject in the Antithrombin III treatment group was missing this data.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516.11" spread="30.292"/>
                    <measurement group_id="O2" value="415.00" spread="31.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0209</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Blood Products</title>
        <description>Number of units of packed red blood cells, fresh frozen plasma, and/or platelets needed</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Blood Products</title>
          <description>Number of units of packed red blood cells, fresh frozen plasma, and/or platelets needed</description>
          <population>Intent-to-treat set</population>
          <units>Units</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Packed Red Blood Cells (Anbinex n=45,Control n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.711" spread="3.551"/>
                    <measurement group_id="O2" value="41.987" spread="3.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fresh frozen plasma (Anbinex n=16, Control n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.188" spread="1.646"/>
                    <measurement group_id="O2" value="13.125" spread="2.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (Anbinex n=5, Control n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.500" spread="1.564"/>
                    <measurement group_id="O2" value="6.188" spread="1.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Number of units of packed red blood cells</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7433</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Units of fresh frozen plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7453</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Units of platelets</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2705</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Needing Surgical Re-exploration</title>
        <description>Percentage of subjects needing surgical re-exploration resulting from bleeding</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set. Two subjects in the Antithrombin III treatment group and 2 subjects in the Control group were missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Needing Surgical Re-exploration</title>
          <description>Percentage of subjects needing surgical re-exploration resulting from bleeding</description>
          <population>Intent-to-treat set. Two subjects in the Antithrombin III treatment group and 2 subjects in the Control group were missing this data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4460</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Low Cardiac Syndrome</title>
        <description>Percentage of subjects with low cardiac syndrome defined as the need for major inotropic support or intra-aortic balloon pump</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set. Three subjects in the Antithrombin III treatment group and 1 subject in the Control group were missing this data.</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Low Cardiac Syndrome</title>
          <description>Percentage of subjects with low cardiac syndrome defined as the need for major inotropic support or intra-aortic balloon pump</description>
          <population>Intent-to-treat set. Three subjects in the Antithrombin III treatment group and 1 subject in the Control group were missing this data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4936</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Renal Dysfunction</title>
        <description>Percentage of subjects with renal dysfunction defined as an increase of serum creatinine levels to &gt;2.0 and twice the baseline level or need for renal replacement therapy</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Renal Dysfunction</title>
          <description>Percentage of subjects with renal dysfunction defined as an increase of serum creatinine levels to &gt;2.0 and twice the baseline level or need for renal replacement therapy</description>
          <population>Intent-to-treat set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up visit (Anbinex n=75, Control n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU discharge visit (Anbinex n=99, Control n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Follow-up visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ICU discharge visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6218</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanical Ventilation Duration</title>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <population>Intent-to-treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Ventilation Duration</title>
          <population>Intent-to-treat set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9574</p_value>
            <method>Hodges-Lehmann</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Length of hospital stay (days) in both groups was defined as the discharge date minus the surgery date plus 1 day, during a maximum of 70 days after ICU admission.</description>
        <time_frame>During ICU stay (maximum 70 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antithrombin III Treatment Group</title>
            <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>No preoperative ATIII supplementation administered</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Length of hospital stay (days) in both groups was defined as the discharge date minus the surgery date plus 1 day, during a maximum of 70 days after ICU admission.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="8.00" upper_limit="13.50"/>
                    <measurement group_id="O2" value="10.00" lower_limit="8.00" upper_limit="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7489</p_value>
            <method>Hodges-Lehmann test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of the Recruitment Visit (Day -14) to the Follow-up Visit (Day 50 +/- 20 days)</time_frame>
      <desc>206 subjects were randomized; six were screen failures. 199 subject were included in the Safety population (100 Anbinex and 99 control).One subject in the control group was excluded from the safety population as Anbinex was administered during the ICU stay.</desc>
      <group_list>
        <group group_id="E1">
          <title>Antithrombin III Treatment Group</title>
          <description>Preoperative ATIII supplementation administered immediately after anesthesia induction
Antithrombin III: Single dose of antithrombin III sufficient to achieve a preoperative level of 120%</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>No preoperative ATII supplementation administered</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Staphyloccal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Wound infection Staphyloccal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vasoplegia syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Enterococcus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Seroconversion test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Staphylcoccus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic behavior</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Evidence based treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tricuspid valve repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemodynamic instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="100"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnoa</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="100"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Diuretic therapy</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="100"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site may publish results from the Study, after providing Sponsor thirty days’ notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsor’s request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsor’s request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor’s Inventions.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Ken Woodward, BSc, M.Sc</name_or_title>
      <organization>GrifolsTherapeutics Inc.</organization>
      <phone>+1 919-316-6675</phone>
      <email>michael.woodward@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

